More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$7.58B
EPS
1.27
P/E ratio
288.5
Price to sales
15.77
Dividend yield
--
Beta
0.537523
Previous close
$72.94
Today's open
$72.31
Day's range
$68.63 - $72.62
52 week range
$28.66 - $126.38
show more
CEO
Joseph K. Belanoff
Employees
730
Headquarters
Redwood City, CA
Exchange
NASDAQ Capital Market
Shares outstanding
109443109
Issue type
Common Stock
Healthcare
Biotechnology & Life Sciences
ESMO Rare Cancers Publishes Case Report Detailing Eight-Year Response to Relacorilant Plus Nab-Paclitaxel in Metastatic Vulvar Cancer
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced publication of a peer-reviewed case report in ESMO Rare Cancers, regarding an approximately eight-year response to relacorilant plus nab-paclitaxel in a patient with metastatic vulva.
Business Wire • Nov 16, 2026

CORT's Q3 Earnings Beat, Higher Product Sales Aid Y/Y Revenues
Corcept's Q3 earnings and revenues beat estimates, driven by strong Lifyorli uptake and higher Korlym sales, as the company advances its pipeline.
Zacks Investment Research • Nov 4, 2026

Corcept Therapeutics Q3 Earnings Call Highlights
Corcept Therapeutics NASDAQ: CORT reported third-quarter 2026 revenue of $340.5 million, up 33% from the prior quarter and 64% from a year earlier, as growth in its endocrinology business and the launch of ovarian cancer treatment Lifyorli lifted results.
MarketBeat • Nov 4, 2026

Corcept Therapeutics Incorporated (CORT) Q3 2026 Earnings Call Transcript
Corcept Therapeutics Incorporated (CORT) Q3 2026 Earnings Call Transcript
Seeking Alpha • Nov 4, 2026

Corcept Therapeutics Announces Third Quarter Financial Results and Provides Corporate Update
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today reported its results for the third quarter. Financial Results “Awareness of the importance of diagnosing and treating patients with Cushing's syndrome is steadily increasing and is driving the.
Business Wire • Nov 3, 2026

Corcept Therapeutics (CORT) Q3 Earnings and Revenues Surpass Estimates
Corcept Therapeutics (CORT) came out with quarterly earnings of $1.01 per share, beating the Zacks Consensus Estimate of $0.68 per share. This compares to earnings of $0.16 per share a year ago.
Zacks Investment Research • Nov 3, 2026

Corcept Therapeutics to Announce Third Quarter Financial Results, Provide Corporate Update and Host Conference Call
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report third quarter financial results and provide a corporate update on November 3, 2026. The company will also host a conference call that day at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time). Conference Call Information Participants must register in advance of the conference call by clicking here. Upon registering, each participant will receive a dial-in number and a unique acces.
Business Wire • Oct 27, 2026

Corcept Reports Positive Results from Phase 2 BELLA Trial of Lifyorli® Combined with Nab-Paclitaxel and Bevacizumab in Patients with Platinum-Resistant Ovarian Cancer
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced positive results from Part A of the company's Phase 2 BELLA trial, which evaluated Lifyorli in combination with nab-paclitaxel and bevacizumab in 95 patients with platinum-resistant.
Business Wire • Oct 26, 2026

2026 ADA/EASD Consensus Report Recommends Screening for Hypercortisolism in Patients with Difficult-to-Control Type 2 Diabetes
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) published their consensus report on the Management of Type 2 Diabetes, 2026.
Business Wire • Oct 20, 2026

Can Lifyorli Aid Corcept's Long-Term Growth Prospects Beyond Korlym?
CORT banks on newly approved drug, Lifyorli, while potential new approvals and clinical studies could help diversify revenues beyond Korlym.
Zacks Investment Research • Oct 19, 2026

¹ Disclosures

Open an M1 investment account to buy and sell Corcept Therapeutics Incorporated commission-free¹. Build wealth for the long term using automated trading and transfers.